Primary cutaneous follicle centre lymphoma medical therapy: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
No edit summary
Line 9: Line 9:
* Radiation using multiple radiation fields is given if the disease has wider extent with grouped lesions.<ref name="Jaffe_2011_1" />{{rp|314}}<ref name="Armitage_2010_2">{{Cite book | last=Armitage | first=JO|author2=Mauch PM |author3=Harris NL |title=Non-Hodgkin Lymphomas| publisher=Lippincott Williams & Wilkins| year=2010 | chapter=Chapter 24|edition=2nd |isbn= 9780781791168|display-authors=etal}}</ref><ref name="Sokol2012" /><ref name="Wilcox2015">{{cite journal |authors=Wilcox RA |title=Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management |journal=Am. J. Hematol. |volume=90 |issue=1 |pages=73–6 |year=2015 |pmid=25535037 |doi=10.1002/ajh.23863 |url=}}</ref>
* Radiation using multiple radiation fields is given if the disease has wider extent with grouped lesions.<ref name="Jaffe_2011_1" />{{rp|314}}<ref name="Armitage_2010_2">{{Cite book | last=Armitage | first=JO|author2=Mauch PM |author3=Harris NL |title=Non-Hodgkin Lymphomas| publisher=Lippincott Williams & Wilkins| year=2010 | chapter=Chapter 24|edition=2nd |isbn= 9780781791168|display-authors=etal}}</ref><ref name="Sokol2012" /><ref name="Wilcox2015">{{cite journal |authors=Wilcox RA |title=Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management |journal=Am. J. Hematol. |volume=90 |issue=1 |pages=73–6 |year=2015 |pmid=25535037 |doi=10.1002/ajh.23863 |url=}}</ref>
* For the less common situation of more extensive disease (still confined to skin), [[rituximab]] without chemotherapy is used.<ref name="Jaffe_2011_1">{{Cite book | last=Jaffe | first=ES | coauthors=Harris NL, Vardiman JW, Campo E, Arber, DA.|title=Hematopathology | publisher=Elsevier Saunders| year=2011 | chapter=|edition=1st |isbn= 9780721600406}}</ref><ref name="Armitage_2010_2">{{Cite book | last=Armitage | first=JO|author2=Mauch PM |author3=Harris NL |title=Non-Hodgkin Lymphomas| publisher=Lippincott Williams & Wilkins| year=2010 | chapter=Chapter 24|edition=2nd |isbn= 9780781791168|display-authors=etal}}</ref><ref name="Sokol2012">{{cite journal |authors=Sokol L, Naghashpour M, Glass LF |title=Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management |journal=Cancer Control |volume=19 |issue=3 |pages=236–44 |year=2012 |pmid=22710899 |doi= |url=}}</ref><ref name="Wilcox2015">{{cite journal |authors=Wilcox RA |title=Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management |journal=Am. J. Hematol. |volume=90 |issue=1 |pages=73–6 |year=2015 |pmid=25535037 |doi=10.1002/ajh.23863 |url=}}</ref>Intralesional [[interferon alpha]] (IFN-α)<ref name="Senff2008">{{cite journal  |vauthors=Senff NJ, Noordijk EM, Kim YH, etal |title=European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas |journal=Blood |volume=112 |issue=5 |pages=1600–9 |year=2008 |pmid=18567836 |doi=10.1182/blood-2008-04-152850 |url=}}</ref>and intralesional [[rituximab]] have been used.<ref name="Jaffe_2011_1">{{Cite book | last=Jaffe | first=ES | coauthors=Harris NL, Vardiman JW, Campo E, Arber, DA.|title=Hematopathology | publisher=Elsevier Saunders| year=2011 | chapter=|edition=1st |isbn= 9780721600406}}</ref><ref name="Senff2008">{{cite journal  |vauthors=Senff NJ, Noordijk EM, Kim YH, etal |title=European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas |journal=Blood |volume=112 |issue=5 |pages=1600–9 |year=2008 |pmid=18567836 |doi=10.1182/blood-2008-04-152850 |url=}}</ref>
* For the less common situation of more extensive disease (still confined to skin), [[rituximab]] without chemotherapy is used.<ref name="Jaffe_2011_1">{{Cite book | last=Jaffe | first=ES | coauthors=Harris NL, Vardiman JW, Campo E, Arber, DA.|title=Hematopathology | publisher=Elsevier Saunders| year=2011 | chapter=|edition=1st |isbn= 9780721600406}}</ref><ref name="Armitage_2010_2">{{Cite book | last=Armitage | first=JO|author2=Mauch PM |author3=Harris NL |title=Non-Hodgkin Lymphomas| publisher=Lippincott Williams & Wilkins| year=2010 | chapter=Chapter 24|edition=2nd |isbn= 9780781791168|display-authors=etal}}</ref><ref name="Sokol2012">{{cite journal |authors=Sokol L, Naghashpour M, Glass LF |title=Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management |journal=Cancer Control |volume=19 |issue=3 |pages=236–44 |year=2012 |pmid=22710899 |doi= |url=}}</ref><ref name="Wilcox2015">{{cite journal |authors=Wilcox RA |title=Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management |journal=Am. J. Hematol. |volume=90 |issue=1 |pages=73–6 |year=2015 |pmid=25535037 |doi=10.1002/ajh.23863 |url=}}</ref>Intralesional [[interferon alpha]] (IFN-α)<ref name="Senff2008">{{cite journal  |vauthors=Senff NJ, Noordijk EM, Kim YH, etal |title=European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas |journal=Blood |volume=112 |issue=5 |pages=1600–9 |year=2008 |pmid=18567836 |doi=10.1182/blood-2008-04-152850 |url=}}</ref>and intralesional [[rituximab]] have been used.<ref name="Jaffe_2011_1">{{Cite book | last=Jaffe | first=ES | coauthors=Harris NL, Vardiman JW, Campo E, Arber, DA.|title=Hematopathology | publisher=Elsevier Saunders| year=2011 | chapter=|edition=1st |isbn= 9780721600406}}</ref><ref name="Senff2008">{{cite journal  |vauthors=Senff NJ, Noordijk EM, Kim YH, etal |title=European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas |journal=Blood |volume=112 |issue=5 |pages=1600–9 |year=2008 |pmid=18567836 |doi=10.1182/blood-2008-04-152850 |url=}}</ref>
* Approximately one-third of primary cutaneous follicle centre lymphoma relapse, usually in the skin; treatment is similar to initial management<ref name="Wilcox2015">{{cite journal |authors=Wilcox RA |title=Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management |journal=Am. J. Hematol. |volume=90 |issue=1 |pages=73–6 |year=2015 |pmid=25535037 |doi=10.1002/ajh.23863 |url=}}</ref> and overall survival remains excellent.<ref name="Suárez2013_2">{{cite journal  |vauthors=Suárez AL, Querfeld C, Horwitz S, etal |title=Primary cutaneous B-cell lymphomas: part II. Therapy and future directions |journal=J. Am. Acad. Dermatol. |volume=69 |issue=3 |pages=343.e1–11; quiz 355–6 |year=2013 |pmid=23957985 |doi=10.1016/j.jaad.2013.06.011 |url=}}</ref>
*There are mixed results of CHOP and R-CHOP.  In one study on 104 patients CHOP chemotherapy demonstrated complete responses in 85 percent of the patients.<ref name="pmid18567836">{{cite journal| author=Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L et al.| title=European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. | journal=Blood | year= 2008 | volume= 112 | issue= 5 | pages= 1600-9 | pmid=18567836 | doi=10.1182/blood-2008-04-152850 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18567836  }} </ref>
*There are mixed results of CHOP and R-CHOP.  In one study on 104 patients CHOP chemotherapy demonstrated complete responses in 85 percent of the patients.<ref name="pmid18567836">{{cite journal| author=Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L et al.| title=European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. | journal=Blood | year= 2008 | volume= 112 | issue= 5 | pages= 1600-9 | pmid=18567836 | doi=10.1182/blood-2008-04-152850 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18567836  }} </ref>
*There are also published case reports presented clinical responses to topical class 1 corticosteroids.<ref name="pmid23957985">{{cite journal| author=Suárez AL, Querfeld C, Horwitz S, Pulitzer M, Moskowitz A, Myskowski PL| title=Primary cutaneous B-cell lymphomas: part II. Therapy and future directions. | journal=J Am Acad Dermatol | year= 2013 | volume= 69 | issue= 3 | pages= 343.e1-11; quiz 355-6 | pmid=23957985 | doi=10.1016/j.jaad.2013.06.011 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23957985  }} </ref>
*There are also published case reports presented clinical responses to topical class 1 corticosteroids.<ref name="pmid23957985">{{cite journal| author=Suárez AL, Querfeld C, Horwitz S, Pulitzer M, Moskowitz A, Myskowski PL| title=Primary cutaneous B-cell lymphomas: part II. Therapy and future directions. | journal=J Am Acad Dermatol | year= 2013 | volume= 69 | issue= 3 | pages= 343.e1-11; quiz 355-6 | pmid=23957985 | doi=10.1016/j.jaad.2013.06.011 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23957985  }} </ref>
* Approximately one-third of primary cutaneous follicle centre lymphoma relapse, usually in the skin; treatment is similar to initial management<ref name="Wilcox2015">{{cite journal |authors=Wilcox RA |title=Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management |journal=Am. J. Hematol. |volume=90 |issue=1 |pages=73–6 |year=2015 |pmid=25535037 |doi=10.1002/ajh.23863 |url=}}</ref> and overall survival remains excellent.<ref name="Suárez2013_2">{{cite journal  |vauthors=Suárez AL, Querfeld C, Horwitz S, etal |title=Primary cutaneous B-cell lymphomas: part II. Therapy and future directions |journal=J. Am. Acad. Dermatol. |volume=69 |issue=3 |pages=343.e1–11; quiz 355–6 |year=2013 |pmid=23957985 |doi=10.1016/j.jaad.2013.06.011 |url=}}</ref>


==References==
==References==

Revision as of 16:20, 29 October 2019

Primary cutaneous follicle centre lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Primary cutaneous follicle centre lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Primary cutaneous follicle centre lymphoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Primary cutaneous follicle centre lymphoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Primary cutaneous follicle centre lymphoma medical therapy

CDC on Primary cutaneous follicle centre lymphoma medical therapy

Primary cutaneous follicle centre lymphoma medical therapy in the news

Blogs on Primary cutaneous follicle centre lymphoma medical therapy

Directions to Hospitals Treating Splenic marginal zone lymphoma

Risk calculators and risk factors for Primary cutaneous follicle centre lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overvew

The predominant therapy for primary cutaneous follicle centre lymphoma is radiotherapy. Adjunctive chemotherapy may be required.[1][2]

Medical Therapy

  • Surgical removal and/or radiotherapy is given for localized disease.[1][2]
  • Radiation using multiple radiation fields is given if the disease has wider extent with grouped lesions.[1]:314[3][4][2]
  • For the less common situation of more extensive disease (still confined to skin), rituximab without chemotherapy is used.[1][3][4][2]Intralesional interferon alpha (IFN-α)[5]and intralesional rituximab have been used.[1][5]
  • There are mixed results of CHOP and R-CHOP. In one study on 104 patients CHOP chemotherapy demonstrated complete responses in 85 percent of the patients.[6]
  • There are also published case reports presented clinical responses to topical class 1 corticosteroids.[7]
  • Approximately one-third of primary cutaneous follicle centre lymphoma relapse, usually in the skin; treatment is similar to initial management[2] and overall survival remains excellent.[8]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Jaffe, ES (2011). Hematopathology (1st ed.). Elsevier Saunders. ISBN 9780721600406. Unknown parameter |coauthors= ignored (help)
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Wilcox RA (2015). "Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management". Am. J. Hematol. 90 (1): 73–6. doi:10.1002/ajh.23863. PMID 25535037.
  3. ↑ 3.0 3.1 Armitage, JO; Mauch PM; Harris NL; et al. (2010). "Chapter 24". Non-Hodgkin Lymphomas (2nd ed.). Lippincott Williams & Wilkins. ISBN 9780781791168.
  4. ↑ 4.0 4.1 Sokol L, Naghashpour M, Glass LF (2012). "Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management". Cancer Control. 19 (3): 236–44. PMID 22710899.
  5. ↑ 5.0 5.1 Senff NJ, Noordijk EM, Kim YH, et al. (2008). "European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas". Blood. 112 (5): 1600–9. doi:10.1182/blood-2008-04-152850. PMID 18567836.
  6. ↑ Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L; et al. (2008). "European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas". Blood. 112 (5): 1600–9. doi:10.1182/blood-2008-04-152850. PMID 18567836.
  7. ↑ Suárez AL, Querfeld C, Horwitz S, Pulitzer M, Moskowitz A, Myskowski PL (2013). "Primary cutaneous B-cell lymphomas: part II. Therapy and future directions". J Am Acad Dermatol. 69 (3): 343.e1–11, quiz 355-6. doi:10.1016/j.jaad.2013.06.011. PMID 23957985.
  8. ↑ Suárez AL, Querfeld C, Horwitz S, et al. (2013). "Primary cutaneous B-cell lymphomas: part II. Therapy and future directions". J. Am. Acad. Dermatol. 69 (3): 343.e1–11, quiz 355–6. doi:10.1016/j.jaad.2013.06.011. PMID 23957985.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Primary_cutaneous_follicle_centre_lymphoma_medical_therapy&oldid=1586591"